shelf(0)

No. 009 · GH & Growth · Growth Hormone

CJC-1295 (with DAC)

CJC-1295 with DACDAC:GRF

A Tier A · Controlled human trials how tiers work →
  • Not FDA approved
  • WADA ✗ S2
Compare Cite
Fingerprint no sequence
CJC-1295 (with DAC) (no defined sequence)

No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.

01

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER A — At least one published randomized controlled trial in humans.

Randomized, placebo-controlled dose studies in healthy adults were published (2006); development was discontinued and it is not approved.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

02

At a glance

Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved
WADA
Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
03

Overview

A long-acting growth hormone releasing hormone analog with a drug-affinity complex that extends its half-life to several days. Provides sustained GH elevation with less frequent dosing.

Research status Phase II clinical trials completed; demonstrated sustained GH elevation in human subjects

04

Mechanism

CJC-1295 DAC is a synthetic GHRH analog with four amino acid substitutions for enzymatic stability plus a drug affinity complex (DAC) that binds albumin, extending the half-life to 6-8 days. It binds the GHRH receptor on pituitary somatotrophs, activating cAMP-PKA signaling to promote sustained GH secretion.

05

Effects reported in research

Reported outcomes, not promises. Some come from controlled human trials; others may be from smaller or preclinical studies — check the studies below.

  • Sustained growth hormone elevation over days
  • Improved body composition
  • Enhanced recovery and deep sleep
  • Increased IGF-1 levels
06

Safety & unknowns

Phase II trials showed generally well-tolerated profile. Common side effects include injection site reactions, water retention, and transient numbness/tingling. Sustained GH elevation may carry risks of prolonged IGF-1 increase. Not FDA-approved.

Unknowns. Trial safety data apply to the populations, formulations and conditions studied.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

07

Studies [1]

  1. Clinical trial 2006

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

    Teichman SL, et al. Journal of Clinical Endocrinology and Metabolism

    Human study demonstrating CJC-1295 produces sustained GH and IGF-1 elevations for 6+ days after a single injection.

    [pubmed]

09

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

10

Cite this entry

$ cite --format=apa

peptidemeta. (2026). CJC-1295 (with DAC). In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/cjc-1295-dac/

$ cite --format=bibtex 
@misc{peptidemeta-cjc-1295-dac,
  title = {CJC-1295 (with DAC)},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/cjc-1295-dac/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open